Cygnus Raises $19.6 Million for Highly Accurate Sequencing Technology

Cygnus Biosciences, a Beijing company developing a novel sequencing technology, raised $19.6 million in a B Round. Cygnus is built on sequencing breakthroughs that it acquired from a Peking University team. Combining an innovative fluorogenic sequencing method with an information theory error-correction algorithm, Cygnus's technology offers error-free sequences of up to 200 base pairs. The financing was led by Zhonguancun Development Group and Shanghai Creation Investment Management. More details.... Share this with colleagues: // //